Valuation: Antengene Corporation Limited

Market Cap 2.08B 2.4B 306M 268M 247M 230M 434M 29.06B 443M 2.97B 1.15B 14.27B 1.15B 1.12B 49.65B P/E 2026 *
6.24x
P/E 2027 * -
Enterprise Value 2.08B 2.4B 306M 268M 247M 230M 434M 29.06B 443M 2.97B 1.15B 14.27B 1.15B 1.12B 49.65B EV / Sales 2026 *
2.93x
EV / Sales 2027 * 5.55x
Free-Float
60.38%
Yield 2026 *
-
Yield 2027 * -
1 day+4.25%
1 week+9.85%
Current month+4.25%
1 month-5.15%
3 months-30.83%
6 months-5.88%
Current year-2.90%
1 week 3.22
Extreme 3.22
3.79
1 month 3.22
Extreme 3.22
4.28
Current year 2.76
Extreme 2.76
6.28
1 year 2.68
Extreme 2.68
8.16
3 years 0.5
Extreme 0.5
8.16
5 years 0.5
Extreme 0.5
20.15
10 years 0.5
Extreme 0.5
22.5
Manager TitleAgeSince
Chief Executive Officer 60 2018-08-27
Director of Finance/CFO 44 2020-06-07
Chief Tech/Sci/R&D Officer - 2026-05-19
Director TitleAgeSince
Director/Board Member 59 2023-04-13
Chairman 60 2018-08-27
Director/Board Member 51 2020-11-08
Date Insider Type Main position Quantity % Market Cap.
04-01Other

Chief Executive Officer

600,000 0.0883%
03-23Other

Chief Financial Officer

235,000 0.0346%
03-23Other

Chief Executive Officer

100,000 0.0147%
Change 5-day change 1-year change 3-year change Capi.($)
+4.25%+9.85%+26.90%+138.96% 306M
+1.81%+3.15%+72.38%+130.80% 56.21B
+0.55%+8.49%+77.09%+100.93% 55.38B
+0.93%+4.11%-12.64%-12.98% 23.75B
+0.36%+3.42%+9.61%+407.11% 23.19B
+3.35%+7.92%+39.26%-6.25% 18.14B
+1.22%+5.51%+36.93%-30.23% 16.84B
+1.49%+17.24%+174.91%+344.55% 15.86B
-0.83%+2.06%+23.70%+182.37% 13.56B
+7.52%+13.57%+42.43% - 12.97B
Average +2.02%+6.16%+49.06%+139.47% 23.62B
Weighted average by Cap. +1.44%+6.59%+56.09%+131.84%

Financials

2026 *2027 *
Net sales 708M 818M 104M 91.54M 84.26M 78.51M 148M 9.91B 151M 1.01B 393M 4.87B 391M 383M 16.93B 374M 432M 55.09M 48.37M 44.52M 41.48M 78.24M 5.24B 79.82M 535M 207M 2.57B 207M 202M 8.95B
Net income 308M 356M 45.36M 39.83M 36.66M 34.16M 64.43M 4.31B 65.74M 441M 171M 2.12B 170M 167M 7.37B -247K -285K -36.35K -31.92K -29.38K -27.38K -51.63K -3.46M -52.68K -353K -137K -1.7M -136K -134K -5.9M
Net Debt - -
Logo Antengene Corporation Limited
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
Employees
129
Date Price Change Volume
26-07-02 HK$3.680 +4.25% 1,222,000
26-06-30 HK$3.530 -1.67% 949,301
26-06-29 HK$3.590 +8.79% 1,214,767
26-06-26 HK$3.300 -1.49% 574,057
26-06-25 HK$3.350 -0.30% 2,847,762
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3.058CNY
Average target price
4.379CNY
Spread / Average Target
+43.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 6996 Stock